BCAX

Bicara Therapeutics Inc.

Bicara Therapeutics Inc. (BCAX) has 6 SEC Form 4 filings (22 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 14, 2026.

The most active filer is Chief Financial Officer Hyep Ivan with 5 filings. Insiders have net sold $2.2M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Claire Mazumdar Clemon
  • Employees:55
  • HQ:Boston, MA, US
  • IPO:2024-09-13

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$2.8M

reported sales (SEC code S)

Unique Insiders

4

in the rolling window

Market Cap

$1.8B

latest known value

Source
Mazumdar ClaireFirst filing
Sale$284KJul 14SEC ↗
Sale$808KJul 10SEC ↗
Cohlhepp RyanFirst filing
Sale$818KJul 10SEC ↗
Cohlhepp RyanFirst filing
Sale$16KJul 10SEC ↗
Hyep IvanFirst in 8 months
Sale$188KMay 26SEC ↗
Raben DavidFirst filing
Sale$126KApr 28SEC ↗
Hyep IvanFirst filing
Sale$118KOct 8SEC ↗
Hyep IvanFirst filing
Sale$332KOct 8SEC ↗
Hyep IvanFirst filing
Sale$102KOct 8SEC ↗

Related companies

Bicara Therapeutics Inc. is in the Healthcare sector.